OncoPro Tumor Mutation Burden (TMB) Test in UAE – 7800 AED – DHA Licensed

Executive Summary & Core Metrics

The OncoPro Tumor Mutation Burden (TMB) test is a next-generation sequencing (NGS) assay quantifying somatic mutations per megabase of tumor DNA. It serves as a predictive biomarker for immune checkpoint inhibitor therapy in metastatic solid tumors. Delivered in 15 working days from a single FFPE block, this DHA-compliant test (Lic. 1143) is tailored for oncologists, anti-aging specialists, and bio-repository managers seeking genomically-informed treatment decisions. Sample collection requires a secure medical courier for solid tissue specimen retrieval – mobile phlebotomy is not applicable.

Price: 7,800 AED
Turnaround Time: 15 working days (sample receipt by Tuesday 11:00 AM)
Sample Type: FFPE tissue block (≥10% tumor nuclei)
Methodology: NGS – comprehensive 500+ gene panel
DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
Clinical Interpretation: TMB-High ≥10 mut/Mb – predictive for immunotherapy benefit

Test Overview & Methodology

The OncoPro TMB test employs a validated NGS panel targeting >500 cancer-related genes. DNA extracted from the FFPE block undergoes library preparation, sequencing on a high-throughput platform, and bioinformatics analysis to calculate TMB. The assay achieves 99.9% diagnostic sensitivity with mutation-level resolution, detecting single nucleotide variants, insertions, deletions, and copy number alterations. Results are reported as mutations per megabase (mut/Mb) and include a tumor-only analysis without a matched normal control. The test is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and follows CAP/CLIA-equivalent quality standards.

Feature	OncoPro TMB Test	Closest Alternative
Method	NGS – comprehensive 500+ gene panel	PCR-based limited gene TMB estimation
Precision	99.9% diagnostic sensitivity; mutation-level resolution	Moderate; unable to detect rare variants
Speed (TAT)	15 working days	Often 20+ days
Sample Type	Single FFPE block (≥10% tumor)	May require additional fresh tissue
Regulatory Compliance	DHA Lic. 1143, ISO 9001:2015	Varies by provider

Physician Insight & Safety Protocols

Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA License: 61713011): “This TMB assay provides a quantitative measure of tumor mutational load that can inform immunotherapy decisions, particularly in advanced solid tumors. However, treatment decisions must integrate full clinical context, imaging, and other biomarkers. A high TMB result does not guarantee response, and low TMB does not preclude benefit. Always correlate with histopathology and consult oncology specialists before modifying therapy.”

Advisory – Medication & Safety

Do not discontinue or alter any prescribed medication without explicit instruction from your treating physician. This test is not a substitute for urgent medical care.

Exclusion Criteria & Emergency Red Flags

FFPE block with <10% tumor nuclei – insufficient for reliable TMB calculation.
Tissue severely fragmented or improperly fixed; sample may be rejected.
Missing histopathology report or NGS requisition form (Form 40) – testing deferred.
ER Red Flags: Acute worsening of symptoms (severe pain, breathing difficulty, bleeding) while awaiting results – seek immediate emergency care. The TMB test is not a substitute for urgent oncology evaluation.

Patient FAQ & Clinical Guidance

1. What is tumor mutation burden and how is it used in cancer treatment?

Tumor mutation burden (TMB) is the total number of somatic coding mutations per megabase of tumor DNA. In UAE oncology practice, high TMB (≥10 mut/Mb) often predicts better response to immune checkpoint inhibitors such as pembrolizumab. Oncologists use this biomarker to select patients most likely to benefit from immunotherapy, integrating it with PD-L1 status and microsatellite instability.

2. What are the sample requirements for the OncoPro TMB test?

Only one FFPE tumor block containing at least 10% neoplastic cells is required, accompanied by a histopathology report. The tissue is sent at room temperature via medical courier (no cold chain needed). A fully completed NGS requisition form (Form 40) must be attached. No blood draw or fresh tissue is necessary.

3. How long does it take to get TMB results in UAE?

Results are reported within 15 working days after sample receipt (cutoff Tuesday 11:00 AM). You will receive a secure, DHA-compliant report via email or patient portal. Our clinical team offers telephonic guidance to help with interpretation and next steps.

4. Will insurance cover the OncoPro TMB test?

Many UAE insurance plans cover advanced genomic testing. Submit your policy details via WhatsApp +971 54 548 8731 for pre-authorization and billing verification. Our team assists with direct insurance billing.

UAE Regulatory & Data Privacy Adherence

This test is performed under DHA Facility License No. 1143 and adheres to the following UAE legal frameworks:

Data Protection: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – personal health data is secured and never shared without explicit consent.
Health Information Technology: Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – ensures secure electronic health data handling.
Medical Liability: Federal Decree-Law No. 4 of 2016 on Medical Liability – governs clinical testing safety and patient consent.
Quality Management: ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) covers all pre-analytical, analytical, and post-analytical phases.

For insurance billing verification and appointment scheduling, contact us via WhatsApp at +971 54 548 8731 (available 8 AM – 11 PM daily).

Clinical & Logistical Metadata

Test Name	OncoPro Tumor Mutation Burden (TMB) Test
Price (AED)	7,800
Turnaround Time	15 working days
Sample Type / Matrix	FFPE tumor block (≥10% tumor nuclei) – Archival Tissue Specimen. Secure medical courier for solid tissue specimen retrieval. Home phlebotomy not applicable.
Methodology Used	Next-Generation Sequencing (NGS) – comprehensive 500+ gene panel
ICD-10-CM Code	C80.1 (Malignant neoplasm without specification of site), Z85.9 (Personal history of malignant neoplasm, unspecified)
LOINC Code	86900-0 (Tumor mutation burden [Ratio] in Tumor tissue)
DHA Facility License & Laboratory Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

💬 التحقق عبر الواتساب Verify via WhatsApp 📞 Call Team

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians